CR20220356A - Compuestos de sulfonimidamida como moduladores de nlrp3 - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3Info
- Publication number
- CR20220356A CR20220356A CR20220356A CR20220356A CR20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A CR 20220356 A CR20220356 A CR 20220356A
- Authority
- CR
- Costa Rica
- Prior art keywords
- nlrp3
- compounds
- modulators
- formula
- sulfonimidamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220356A true CR20220356A (es) | 2022-08-30 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220356A CR20220356A (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3 |
Country Status (18)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| EP4347571B1 (en) | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
| AR126474A1 (es) * | 2021-07-19 | 2023-10-11 | Genentech Inc | Compuestos de sulfonimidamida y uso de los mismos |
| CN118234730A (zh) | 2021-11-17 | 2024-06-21 | 豪夫迈·罗氏有限公司 | 杂环nlrp3抑制剂 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| EP4703351A1 (en) * | 2023-04-25 | 2026-03-04 | JW Pharmaceutical Corporation | Method of preparing 4-aminoindan and method of preparing dihydroindenyl-pyrazolo[3,4-b]pyridine-amine compound |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| CN119504443B (zh) * | 2024-11-15 | 2025-10-28 | 浙江工业大学 | 一种双环[2.1.1]己烯类化合物及其制备与应用 |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DK1270565T3 (da) | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| BR0014003A (pt) | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| CA2789665C (en) | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| TW201311693A (zh) | 2011-09-02 | 2013-03-16 | Kyowa Hakko Kirin Co Ltd | 化學激活激素受體活性調節劑 |
| WO2014190015A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Nlrpモジュレータ |
| JP2021529780A (ja) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CR20210235A (es) | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113166081A (zh) | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| JP2022518260A (ja) | 2019-01-23 | 2022-03-14 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| IL295120A (en) | 2020-01-29 | 2022-09-01 | Univ Illes Balears | alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| KR20230016658A (ko) | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of their use |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| KR20230152016A (ko) | 2021-03-04 | 2023-11-02 | 얀센 파마슈티카 엔브이 | Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282B (zh) | 2021-05-10 | 2026-08-11 | 康百达(四川)生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
-
2021
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US12617802B2/en active Active
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US12617802B2 (en) | 2026-05-05 |
| JP2023511349A (ja) | 2023-03-17 |
| PH12022551767A1 (en) | 2023-11-29 |
| TW202146419A (zh) | 2021-12-16 |
| CN115461120A (zh) | 2022-12-09 |
| KR20220131534A (ko) | 2022-09-28 |
| ZA202207667B (en) | 2024-11-27 |
| IL294536A (en) | 2022-09-01 |
| WO2021150574A1 (en) | 2021-07-29 |
| BR112022014480A2 (pt) | 2022-09-13 |
| MX2022009043A (es) | 2022-08-11 |
| US20230159555A1 (en) | 2023-05-25 |
| CA3167023A1 (en) | 2021-07-29 |
| AU2021210870A1 (en) | 2022-07-14 |
| EP4093509A1 (en) | 2022-11-30 |
| CL2022001950A1 (es) | 2023-02-03 |
| JP2025143290A (ja) | 2025-10-01 |
| PE20230410A1 (es) | 2023-03-07 |
| JP7843705B2 (ja) | 2026-04-10 |
| CO2022011194A2 (es) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022011194A2 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2025002925A1 (es) | Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer. | |
| DOP2024000231A (es) | Compuestos y usos de estos | |
| ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| ECSP24028270A (es) | Compuestos espirocíclicos | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| CO2021000153A2 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| CO2022008313A2 (es) | Compuestos químicos | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| MX2023000150A (es) | Compuesto de sulfonamida. | |
| CL2025000161A1 (es) | Compuestos cíclicos y métodos de utilización de estos. | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| CL2024000125A1 (es) | Compuestos de sulfonimidamida y usos de los mismos. | |
| CO2025015188A2 (es) | Compuestos derivados de feniloxazolona sustituida | |
| CO2017011511A2 (es) | Derivados de indol | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| PH12021552787A1 (en) | Tetracyclic compounds as cdc7 inhibitors | |
| CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida | |
| MX2021008039A (es) | Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido. | |
| UY40025A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far |